Illumina, Inc.

ILU.DE

ILU.DEIllumina, Inc. DE flag

Deutsche Börse

77.75

EUR

-0.33

(-0.42%)

-7.09EPS

-10.97P/E

12.32BMarket Cap

Apr 30Next Earn

Illumina, Inc.

ILU.DE

(Deutsche Börse)

Recent

price

77.75

P/E

ratio

-10.97

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 03/18

Stock

S&P500

-28.60

18.57

-68.18

40.07

-65.51

86.07

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
4.91	5.41	7.3	8.55	9.34	11.36	13.73	15.33	16.34	18.85	22.67	24.1	22.03	30.17	29.2	28.51	27.61	Revenue per Share
0.34	0.59	1.01	0.7	1.23	1	2.61	3.19	3.15	4.97	5.62	6.82	4.46	5.08	-28.05	-7.35	-9.96	Basic EPS, GAAP
-0.07	0.94	1.75	2.26	1.71	2.37	2.65	4.44	3.46	3.86	5.76	5.73	6.06	2.25	-0.47	1.78	3.44	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
-3	-2.26	-1.24	-0.54	0.68	1.68	4.15	7.07	10.13	15.47	20.99	27.68	32.14	36.58	7.29	-0.11	-8.97	Book Value per Share
4.6	4.93	6.87	5.24	6.66	3.83	3.12	5.68	8.53	12.35	19.24	24.79	24.86	2.51	0.48	1.31	4.45	Tangible Book Value per Share
117	123	124	123	123	125	136	145	147	146	147	147	147	150	157	158	159	Basic Weighted Avg Shares
573	666	903	1,056	1,149	1,421	1,861	2,220	2,398	2,752	3,333	3,543	3,239	4,526	4,584	4,504	4,390	Sales/Revenue/Turnover
19.05	18.85	22.5	23.72	22.33	17.88	23.82	28.47	24.1	22.02	26.49	27.8	17.91	-2.72	7.72	-4.93	5.44	Operating Margin (%)
28	31	42	69	65	98	113	127	141	156	179	188	187	251	394	432	392	Depreciation Expense
39	72	125	87	151	125	353	462	463	726	826	1,002	656	762	-4,404	-1,161	-1,584	Net Income, GAAP
45.77	36.67	32.63	34.89	32.05	21.35	21.26	21.44	23.71	35	12.53	11.45	23.36	13.8	- -	- -	2.08	Effective Tax Rate (%)
6.88	10.85	13.83	8.21	13.17	8.82	18.98	20.81	19.31	26.38	24.78	28.28	20.25	16.84	-96.07	-25.78	-36.08	Profit Margin (%)
483	540	724	1,318	1,482	1,295	1,167	1,486	1,613	2,234	2,686	3,786	3,239	1,620	788	1,039	1,398	Working Capital
- -	- -	- -	807	805	839	987	1,016	1,056	1,182	890	1,836	1,344	2,469	2,231	2,176	2,601	LT Debt
799	864	1,198	1,075	1,319	1,533	1,463	1,849	2,270	2,749	3,845	4,613	4,694	10,740	6,599	5,745	2,125	Total Equity
6.27	7.13	10.28	9.57	8.54	8.66	13.36	17.16	13.42	10.22	15.36	13.96	6.71	-1.06	- -	- -	- -	Return on Invested Capital (%)
-181.96	-277.96	167.21	24.34	21.23	15.61	26.34	25.12	21.07	24.8	20.99	19.07	11.03	11.11	- -	- -	-77.22	Return on Capital (%)
- -	- -	- -	- -	- -	85.28	91.47	58.2	36.87	38.77	30.92	28.01	14.92	14.92	-132.83	- -	- -	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	13.11%	7.4%	-1.75%
Net Income, GAAP	-46.51%	-149.73%	-73.64%
Free Cash Flow	-51.93%	-131.97%	-481.08%
Total Cash Common Dividend	- -	- -	- -
Total Equity	20.46%	19.81%	-12.94%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Lumos Diagnostics Holdings Limited (LDX.AX)
Optigenex Inc. (OPGX)
LungLife AI, Inc. (LLAI.L)
Genetic Technologies Limited (GENE)
CardioGenics Holdings Inc (CGNH)
Epigenomics AG (EPGNY)
Business: Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

	Mar'24	Jun'24	Sep'24
ST Debt	86	815	73
LT Borrowings	1,490	1,490	1,988
LT Finance Leases	700	616	613
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	159	159	158
Market Capitalization	21,938	17,112	20,667

	Mar'24	Jun'24	Sep'24
Total Current Assets	2,583	2,459	2,373
Accounts Receivable, Net	635	641	699
Cash, Cash Equivalents & STI	1,108	994	939
Inventories	584	561	574
Total Current Liabilities	1,474	2,208	975
Payables & Accruals	938	958	430
ST Debt	86	815	73
Deferred Revenue	248	238	235

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
4.91	5.41	7.3	8.55	9.34	11.36	13.73	15.33	16.34	18.85	22.67	24.1	22.03	30.17	29.2	28.51	27.61	Revenue per Share
0.34	0.59	1.01	0.7	1.23	1	2.61	3.19	3.15	4.97	5.62	6.82	4.46	5.08	-28.05	-7.35	-9.96	Basic EPS, GAAP
-0.07	0.94	1.75	2.26	1.71	2.37	2.65	4.44	3.46	3.86	5.76	5.73	6.06	2.25	-0.47	1.78	3.44	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
-3	-2.26	-1.24	-0.54	0.68	1.68	4.15	7.07	10.13	15.47	20.99	27.68	32.14	36.58	7.29	-0.11	-8.97	Book Value per Share
4.6	4.93	6.87	5.24	6.66	3.83	3.12	5.68	8.53	12.35	19.24	24.79	24.86	2.51	0.48	1.31	4.45	Tangible Book Value per Share
117	123	124	123	123	125	136	145	147	146	147	147	147	150	157	158	159	Basic Weighted Avg Shares
573	666	903	1,056	1,149	1,421	1,861	2,220	2,398	2,752	3,333	3,543	3,239	4,526	4,584	4,504	4,390	Sales/Revenue/Turnover
19.05	18.85	22.5	23.72	22.33	17.88	23.82	28.47	24.1	22.02	26.49	27.8	17.91	-2.72	7.72	-4.93	5.44	Operating Margin (%)
28	31	42	69	65	98	113	127	141	156	179	188	187	251	394	432	392	Depreciation Expense
39	72	125	87	151	125	353	462	463	726	826	1,002	656	762	-4,404	-1,161	-1,584	Net Income, GAAP
45.77	36.67	32.63	34.89	32.05	21.35	21.26	21.44	23.71	35	12.53	11.45	23.36	13.8	- -	- -	2.08	Effective Tax Rate (%)
6.88	10.85	13.83	8.21	13.17	8.82	18.98	20.81	19.31	26.38	24.78	28.28	20.25	16.84	-96.07	-25.78	-36.08	Profit Margin (%)
483	540	724	1,318	1,482	1,295	1,167	1,486	1,613	2,234	2,686	3,786	3,239	1,620	788	1,039	1,398	Working Capital
- -	- -	- -	807	805	839	987	1,016	1,056	1,182	890	1,836	1,344	2,469	2,231	2,176	2,601	LT Debt
799	864	1,198	1,075	1,319	1,533	1,463	1,849	2,270	2,749	3,845	4,613	4,694	10,740	6,599	5,745	2,125	Total Equity
6.27	7.13	10.28	9.57	8.54	8.66	13.36	17.16	13.42	10.22	15.36	13.96	6.71	-1.06	- -	- -	- -	Return on Invested Capital (%)
-181.96	-277.96	167.21	24.34	21.23	15.61	26.34	25.12	21.07	24.8	20.99	19.07	11.03	11.11	- -	- -	-77.22	Return on Capital (%)
- -	- -	- -	- -	- -	85.28	91.47	58.2	36.87	38.77	30.92	28.01	14.92	14.92	-132.83	- -	- -	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2022	1,223	1,162	1,115	1,083	4,584
2023	1,087	1,176	1,119	1,122	4,504
2024	1,076	1,112	1,080	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.55	-3.41	-24.31	-0.88	-28.05
2023	0.02	-1.48	-4.77	-1.1	-7.35
2024	-0.79	-12.5	4.43	- -	- -

Illumina, Inc.

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year